Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579057 · ClinicalTrials.gov registry record · Phase 2
Sub-Q Versus IV Furosemide in Acute Heart Failure
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02579057: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT02579057 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02579057, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study evaluates the clinical efficacy of subcutaneously administered Furosemide Injection Solution versus intravenous administration of Furosemide Injection, United States Pharmacopeia (USP) in adult patients presenting to a heart failure clinic with decompensated heart failure. Half of the patients will receive a subcutaneously administered Furosemide Injection Solution; the other half will receive an intravenous administration of Furosemide Injection.
Interventions
- DRUG Furosemide Injection Solution (SCP-101)
- DRUG Furosemide Injection Solution, USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02579057
The ClinicalTrials.gov registry entry for NCT02579057 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Furosemide Injection Solution (SCP-101) is the first listed.
NCT02579057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02579057 about?
NCT02579057 is a clinical study titled "Sub-Q Versus IV Furosemide in Acute Heart Failure". This study evaluates the clinical efficacy of subcutaneously administered Furosemide Injection Solution versus intravenous administration of Furosemide Injection, United States Pharmacopeia (USP) in adult patients presenting to a heart failure clinic with decompensated heart failure. Half of the pat...
What is the current status of trial NCT02579057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2016-02. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02579057?
The interventions under investigation include: Furosemide Injection Solution (SCP-101) (DRUG), Furosemide Injection Solution, USP (DRUG).
Who is sponsoring clinical trial NCT02579057?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.